NCT02140346View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

RV1729 28 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV1729 matching placebo 28 day repeat dose

Safety and tolerability of repeat doses

Trial Locations (2)

BT9 6AD

Belfast

M23 9QZ

Manchester

All Listed Sponsors
lead

Respivert Ltd

INDUSTRY

NCT02140346 - A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD | Biotech Hunter | Biotech Hunter